Peptide, nootropic, and nutraceutical research advances faster than regulatory frameworks can follow. CompoundProfile builds a continuously expanding index using the AI Agent-driven Compound Health Score (AI‑CHS), an analytics engine that aggregates published studies, clinical trial data, and real-world public discourse tracking both the clinical evidence and what's trending online.
Peptides and nootropics are not new. The pace at which new compounds, new delivery mechanisms, and new applications are entering the research pipeline is accelerating well beyond what any regulatory body can realistically evaluate in real time. Compounds that have years of published human and animal trial data sit in regulatory grey zones, not because the science is absent, but because the institutional machinery moves on a different timescale than the labs and the communities actually using them.
CompoundProfile was built to close that information gap. The CHS-AI Agent aggregates signal from published medical literature, trial databases, and weighted public discourse channels to produce two independent scores per compound: an Evidence Score reflecting the quality and depth of the research base, and a Sentiment Score reflecting real-world community experience across forums, biohacker media, and medical press. Together they produce the ICPS: a single, transparent, version-tracked number that tells you where the science actually stands.
Educational use only. CompoundProfile scores are AI-derived research summaries intended to inform, not to replace clinical guidance. Compounds indexed here may be unscheduled, prescription-only, or prohibited depending on jurisdiction. Always verify regulatory status and consult a qualified practitioner before use.
| # | Compound | Category | Evidence | Sentiment | ICPS |
|---|